NEW YORK (GenomeWeb) – Australian molecular diagnostic firm Genetic Technologies today announced a restructuring aimed at ramping up its US molecular diagnostic operations and commercializing the new version of its BrevaGen breast cancer risk test.
NEW YORK (GenomeWeb) – Australian molecular diagnostic firm Genetic Technologies today announced a restructuring aimed at ramping up its US molecular diagnostic operations and commercializing the new version of its BrevaGen breast cancer risk test.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.